Veralto Total Cost of Revenue remained flat by 0.0% to $568.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.8%, from $527.00M to $568.00M. Over 3 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 3.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $496.75M | $496.75M | $496.75M | $525.00M | $537.00M | $517.00M | $529.00M | $532.00M | $542.00M | $499.00M | $514.00M | $531.00M | $544.00M | $527.00M | $549.00M | $560.00M | $568.00M | $568.00M |
| QoQ Change | — | +0.0% | +0.0% | +5.7% | +2.3% | -3.7% | +2.3% | +0.6% | +1.9% | -7.9% | +3.0% | +3.3% | +2.4% | -3.1% | +4.2% | +2.0% | +1.4% | +0.0% |
| YoY Change | — | — | — | +5.7% | +8.1% | — | — | +1.3% | +0.9% | -3.5% | -2.8% | -0.2% | +0.4% | +5.6% | +6.8% | +5.5% | +4.4% | +7.8% |